← Back to Search

Autoimmune Intervention Mastery Course for Multiple Sclerosis (AIM Trial)

N/A
Recruiting
Led By Terry L Wahls, MD
Research Sponsored by Terry L. Wahls
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Self-reported multiple sclerosis
Self-reported clinically isolated syndrome
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline to 6 months
Awards & highlights
No Placebo-Only Group

Summary

This trial will test whether an online program can help improve diet and self-care in patients with MS or CIS.

Who is the study for?
This trial is for individuals with conditions like multiple sclerosis, clinically isolated syndrome, fibromyalgia, or long-lasting symptoms after COVID-19. Participants must have a self-reported diagnosis and persistent fatigue or neuropsychiatric symptoms for over 6 months post-COVID.
What is being tested?
The study tests an online program called Autoimmune Intervention Mastery Course (AIM), which focuses on diet and self-care improvements. It compares immediate access to AIM with delayed access to see how effective the program is.
What are the potential side effects?
Since this trial involves an educational course rather than medication, traditional side effects are not expected. However, participants may experience stress or discomfort from lifestyle changes.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have been diagnosed with multiple sclerosis.
Select...
I have had a single episode of neurological symptoms.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline to 6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline to 6 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Multiple Sclerosis 54 Quality of Life Mental Health (MS 54 QoL MH)
Multiple Sclerosis 54 Quality of Life Physical Health (MS 54 QoL PH)
Short form 36 (SF 36)
+1 more
Secondary study objectives
Brief Pain Inventory
FM Disease activity (FIQR)
Fibromyalgia Impact Questionnaire Revised
+8 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Group I: Intervention Autoimmune Intervention Mastery Course (AIM) online courseExperimental Treatment2 Interventions
This arm will begin the intervention immediately after randomization
Group II: Delayed Autoimmune Intervention Mastery CourseExperimental Treatment2 Interventions
This is the control arm.

Find a Location

Who is running the clinical trial?

Terry L. WahlsLead Sponsor
5 Previous Clinical Trials
321 Total Patients Enrolled
4 Trials studying Multiple Sclerosis
321 Patients Enrolled for Multiple Sclerosis
Terry L Wahls, MDPrincipal InvestigatorUniversity of Iowa
4 Previous Clinical Trials
221 Total Patients Enrolled
3 Trials studying Multiple Sclerosis
221 Patients Enrolled for Multiple Sclerosis

Media Library

Delayed Autoimmune Intervention Mastery Course Clinical Trial Eligibility Overview. Trial Name: NCT05057676 — N/A
Multiple Sclerosis Research Study Groups: Intervention Autoimmune Intervention Mastery Course (AIM) online course, Delayed Autoimmune Intervention Mastery Course
Multiple Sclerosis Clinical Trial 2023: Delayed Autoimmune Intervention Mastery Course Highlights & Side Effects. Trial Name: NCT05057676 — N/A
Delayed Autoimmune Intervention Mastery Course 2023 Treatment Timeline for Medical Study. Trial Name: NCT05057676 — N/A
~32 spots leftby Dec 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top